What is DCN Dx?
DCN Dx operates as a specialized Contract Development and Manufacturing Organization (CDMO) and Clinical Research Organization (CRO), primarily focused on the advancement of point-of-use diagnostic assays. The company is particularly recognized for its expertise in lateral flow test development, providing a comprehensive suite of services that spans from initial assay design to clinical research and regulatory navigation. Headquartered in Carlsbad, California, the firm leverages a purpose-built facility to offer end-to-end solutions for its clients. By integrating multidisciplinary teams into the client development lifecycle, DCN Dx ensures a collaborative and transparent approach to complex diagnostic challenges, effectively bridging the gap between laboratory innovation and commercial-scale manufacturing in the IVD industry.
How much funding has DCN Dx raised?
DCN Dx has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in DCN Dx
PPP
Public-Private Partnership
What's next for DCN Dx?
With the successful acquisition of this recent financing, DCN Dx is poised to scale its infrastructure and enhance its service delivery model. The company's strategic roadmap likely involves deepening its technical capabilities in lateral flow technology and expanding its regulatory support services to meet the evolving demands of the global healthcare market. As the firm transitions through this late-stage growth phase, the focus will remain on maintaining high-quality standards while scaling production capacity to accommodate a growing client base. This capital deployment will be instrumental in sustaining the company's competitive advantage as a premier partner for diagnostic developers seeking to navigate the complexities of clinical validation and commercialization.
See full DCN Dx company page
